School of Medicine
  • Print
   
   

School staff listing

People listings by divisions

 

Lindy Durrant

Professor of Cancer Immunotherapy, Faculty of Medicine & Health Sciences

Contact

Biography

The monoclonal antibody (Mabs) group has developed a unique strategy to generate mabs targeting tumour glycolipidsand have validated this approach by producing two colorectal cancer mabs, licensed to Arana Ltd/Kyowa Hakko for clinical development. Glycolipids are ideal targets for drug discovery as they are aberrantly overexpressed by tumours and are functional co-accessory molecules essential for most physiological processes. Currently the group are producing mabs targeting ovarian, gastric and pancreatic tumour glycolipids The cancer vaccine group have developed a unique DNA vaccine platform to stimulate high avidity T cells which efficiently kill tumour cells. The lead vaccine for the treatment of Melanoma is due to enter the clinic in June 2010

Expertise Summary

The monoclonal antibody (Mabs) group has developed a unique strategy to generate mabs targeting tumour glycolipidsand have validated this approach by producing two colorectal cancer mabs, licensed to Arana Ltd/Kyowa Hakko for clinical development. Glycolipids are ideal targets for drug discovery as they are aberrantly overexpressed by tumours and are functional co-accessory molecules essential for most physiological processes. Currently the group are producing mabs targeting ovarian, gastric and pancreatic tumour glycolipids The cancer vaccine group have developed a unique DNA vaccine platform to stimulate high avidity T cells which efficiently kill tumour cells. The lead vaccine for the treatment of Melanoma is due to enter the clinic in June 2010

Research Summary

cancer vaccines, particular interest is the development of DNA vaccines.

Selected Publications

School of Medicine

University of Nottingham
Medical School
Nottingham, NG7 2UH

Contacts: Please see our 'contact us' page for further details